Substance Misuse To Psychosis for Stimulants
Summary
In Hong Kong, less than 5% of stimulants abusers were reported to misuse these substances via injection. Also, it is well known that patients with co-morbid substance abuse/dependence and psychosis or schizophrenia-related disorders are prone to earlier treatment discontinuation and high oral medication non-adherence, resulting in poorer overall outcomes. With the recent availabilities of the 4-weekly long-acting injectable form of aripiprazole, and the 4-weekly and the 3-monthly long-acting injectable form of paliperidone palmitate, on the background of the surging phenomenon of stimulant misuses in Hong Kong, it is a timely opportunity to conduct an early pharmacotherapy intervention study to offer an evidence-based strategy aiming to stop individuals with substance use disorders with psychosis to develop into a more chronic disabling dependence or co-morbid state.
Timeline
- Start
- 2019-06-01
- Primary completion
- 2024-05-31
- Completion
- 2025-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aripiprazole | Other / unclassified | 10 mg | Oral |
| Comparator | Aripiprazole | Other / unclassified | 30 mg | Oral |
| Comparator | Aripiprazole | Other / unclassified | 300 mg | Oral |
| Comparator | Aripiprazole | Other / unclassified | 400 mg | Oral |
| Comparator | Paliperidone | Unknown | 3 mg | Oral |
| Comparator | Paliperidone | Unknown | 12 mg | Oral |
| Comparator | Paliperidone | Unknown | 50 mg | Oral |
| Comparator | Paliperidone | Unknown | 150 mg | Oral |
| Comparator | Paliperidone | Unknown | 273 mg | Oral |
| Comparator | Paliperidone | Unknown | 819 mg | Oral |